<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812889</url>
  </required_header>
  <id_info>
    <org_study_id>11-0077</org_study_id>
    <secondary_id>HHSN272200800024C</secondary_id>
    <secondary_id>TOL-463</secondary_id>
    <nct_id>NCT01812889</nct_id>
  </id_info>
  <brief_title>Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463</brief_title>
  <official_title>A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, local tolerability and pharmacokinetic&#xD;
      parameters of TOL-463 intravaginal dosage forms in both healthy, nonpregnant females&#xD;
      following single dose administration (Part 1), and in nonpregnant women with vaginitis&#xD;
      following multi-dose administration (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safety, local tolerability and pharmacokinetic&#xD;
      parameters of TOL-463 intravaginal dosage forms in both healthy, nonpregnant females&#xD;
      following single dose administration (Part 1), and in nonpregnant women with vaginitis&#xD;
      following multi-dose administration (Part 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The local (vulvovaginal) and systemic safety and tolerability of TOL-463 gel and ovules following a single intravaginal administration in healthy female subjects and following daily dosing for 7 days in women with BV or VVC will be assessed.</measure>
    <time_frame>Following daily dosing for 1 or 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs) will be monitored throughout the course of the study following administration of Investigational Product (IP).</measure>
    <time_frame>Up to Day 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard PK parameters (half-life, Cmax, Tmax and AUC), will be assessed following single-dose administration of TOL-463 gel and ovule in healthy subjects and after single- and multiple-dose administration of TOL-463 gel or ovules in women with BV or VVC</measure>
    <time_frame>Once daily for 1 or 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Vaginal Infection</condition>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOL-463 Vaginal ovule</intervention_name>
    <description>TOL-463 Vaginal Ovule</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOL-463 Vaginal gel</intervention_name>
    <description>TOL-463 Vaginal Gel</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women of any race between 18 to 45 years of age (inclusive).&#xD;
&#xD;
          -  Subjects must be able to give voluntary written informed consent before any study&#xD;
             related procedure is performed.&#xD;
&#xD;
          -  Subjects must have a negative serum pregnancy test at Screening and negative urine&#xD;
             pregnancy test at all other clinical site visits, as applicable.&#xD;
&#xD;
          -  Subjects either have no childbearing potential (as defined below) (Note 1) or agree to&#xD;
             avoid becoming pregnant from the day of screening through one month after the last&#xD;
             study Day using one of the following acceptable methods of birth control (Note 2) in&#xD;
             addition to the use of non-lubricated condoms by the male partner (even if&#xD;
             vasectomized).&#xD;
&#xD;
               -  Hormonal contraceptives&#xD;
&#xD;
               -  Abstinence&#xD;
&#xD;
               -  Note 1: Non-childbearing potential is defined as being post-menopausal for at&#xD;
                  least 2 years, status after bilateral tubal ligation for at least 1 year, status&#xD;
                  after bilateral oophorectomy or status after hysterectomy.&#xD;
&#xD;
               -  Note 2: Intravaginal or intra-uterine contraceptives and contraceptive devices&#xD;
                  (IUDs) are not acceptable forms of birth control for this study.&#xD;
&#xD;
          -  Subjects must agree to refrain from douching or using any intravaginal products (i.e.,&#xD;
             contraceptive creams, gels, foams, sponges, lubricants, etc.) or IUDs during the study&#xD;
             period.&#xD;
&#xD;
          -  Subjects must agree not to donate blood during the study and up to 14 days after the&#xD;
             end of the study.&#xD;
&#xD;
          -  Subjects willing and able to comply with all study requirements.&#xD;
&#xD;
        For Part 1 Only&#xD;
&#xD;
          -  Subjects must be healthy as determined by medical history, physical examination, vital&#xD;
             signs, pelvic examination and laboratory evaluations (hematology, clinical chemistry&#xD;
             and urinalysis tests) within study-defined ranges at Screening.&#xD;
&#xD;
          -  Subjects must be without current symptomatic or asymptomatic bacterial vaginosis,&#xD;
             candida vulvovaginitis or any other form of vaginitis by clinical and microbiologic&#xD;
             testing.&#xD;
&#xD;
          -  Subjects must be willing to abstain from sexual intercourse for 24 hours prior to each&#xD;
             site visit.&#xD;
&#xD;
        For Part 2 Only&#xD;
&#xD;
          -  Subjects with vaginitis must be otherwise healthy based on medical history, physical&#xD;
             examination, vital signs, pelvic examination and laboratory evaluations (hematology,&#xD;
             clinical chemistry and urinalysis tests) within study-defined ranges at Screening.&#xD;
&#xD;
          -  Subjects with vaginitis must be willing to abstain from sexual intercourse 24 hours&#xD;
             prior to the first dose of study medication and throughout the last visit of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of clinically significant acute illness (resolved within 4 weeks of&#xD;
             screening) or any other condition which, in the opinion of the Site Principal&#xD;
             Investigator (PI), would jeopardize the safety of the subject or impact the validity&#xD;
             of the study results.&#xD;
&#xD;
          -  Subjects with intrauterine devices.&#xD;
&#xD;
          -  Subjects with renal dysfunction (serum creatinine &gt;/= 1.2 mg/dL).&#xD;
&#xD;
          -  Subjects with underlying metabolic or endocrine dysfunction, such as diabetes&#xD;
             mellitus, Cushing's disease, Addison's disease, or hypo- or hyperthyroidism.&#xD;
&#xD;
          -  Subjects who test positive for HIV, hepatitis B surface antigen (HBsAg), or hepatitis&#xD;
             C antibody.&#xD;
&#xD;
          -  Subjects who have diseases known to cause immunodeficiency, e.g., AIDS, advanced&#xD;
             malignancy, anemia or severe vitamin deficiency.&#xD;
&#xD;
          -  Subjects who test positive for Trichomonas vaginalis, Neisseria gonorrhea, or&#xD;
             Chlamydia trachomatis at screening.&#xD;
&#xD;
          -  Subjects with active genital lesions at screening, including syphilitic chancre,&#xD;
             herpetic lesions, or genital warts (HPV).&#xD;
&#xD;
          -  Subjects who have had major surgery within 4 weeks of screening.&#xD;
&#xD;
          -  Subjects with an uncontrolled active illness (e.g., active infection) or fever (oral&#xD;
             temperature &gt;/=100 degrees F or &gt;/= 37.7 degrees C) at screening.&#xD;
&#xD;
          -  Subjects with a known sensitivity to any ingredient in TOL-463 vaginal gel or ovule.&#xD;
&#xD;
          -  With the exception of oral contraceptives, use of a prescription medication, notably&#xD;
             antimicrobial agents, corticosteroids or other immuno-suppressants, within 14 days&#xD;
             prior to Day 1 of study treatment, unless in the opinion of the PI, the substance&#xD;
             would not likely impact the conduct or results of this study.&#xD;
&#xD;
          -  Subjects with any current unstable medical condition(s) requiring prescription&#xD;
             medication(s) that would preclude accurate evaluation of subjects or otherwise impact&#xD;
             the conduct or results of the study.&#xD;
&#xD;
          -  Subjects who have received an investigational drug in a clinical trial within 30 days&#xD;
             prior to screening.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding. Subject has a positive history for alcohol&#xD;
             abuse or dependence and/or a positive urine screen test for alcohol and drugs of abuse&#xD;
             [amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates,&#xD;
             phencyclidine (PCP)] at screening or at any check-in prior to receiving study drug.&#xD;
&#xD;
          -  Subjects who have donated blood within the past 30 days prior to Day 1 of treatment&#xD;
             with study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles Phase I Services - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211-1553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial vaginosis, vulvovaginal candidiasis, TOL-463, intravaginal therapy, vaginitis, women, cross-over</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TOL-463</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

